^
Association details:
| Biomarker: | Chr amplification(1q) |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | bortezomib (Proteasome inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
P-062 The Impact of Bortezomib-Based Induction on Chromosome 1q21 Gained Newly Diagnosed Multiple Myeloma of Chinese Origin
Published date:
08/28/2021
Excerpt:
... we have analysed CD138-sorted bone marrow plasma cells in cases treated with bortezomib based induction therapy...Gain 1q+ was not associated with response rate but did associate with shorter event free survival (EFS) (median EFS: 35 months vs 55 months, p=0.05) and overall survival (OS) (median OS 74 months vs 168, p=0.00025)....Post-relapse/progression survival was inferior in those with 1q+ (median 60 months vs median 118 months, p=0.000316).
